tbuckley/cabot-search huggingface dataset:
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons — Advisory Committee on Immunization Practices, 2016
Authors: Jessica R. MacNeil, Lorry G. Rubin, Monica Patton, Ismael R. Ortega-Sanchez, Stacey W. Martin
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

At its June 2016 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of meningococcal conjugate vaccine (serogroups A, C, W, and Y; including MenACWY-D [Menactra, Sanofi Pasteur] or MenACWY-CRM [Menveo, GlaxoSmithKline]) for persons aged ≥2 months with human immunodeficiency virus (HIV) infection. ACIP has previously recommended routine vaccination of persons aged ≥2 months who have certain medical conditions that increase risk for meningococcal disease (1), including persons who have persistent (e.g., genetic) deficiencies in the complement pathway (e.g., C3, properdin, Factor D, Factor H, or C5-C9); persons receiving eculizumab (Soliris, Alexion Pharmaceuticals) for treatment of atypical hemolytic uremic syndrome or paroxysmal nocturnal hemoglobinuria (because the drug binds C5 and inhibits the terminal complement pathway); and persons with functional or anatomic asplenia (including persons with sickle cell disease). Routine vaccination with meningococcal conjugate vaccine is also recommended for all healthy adolescents in the United States (1). This report summarizes the evidence considered by ACIP in recommending vaccination for HIV-infected persons, and provides recommendations and guidance for use of meningococcal conjugate vaccines (serogroups A, C, W, and Y) among HIV-infected persons aged ≥2 months; the majority of meningococcal disease among HIV-infected persons is caused by these four serogroups.
Mutation Analysis of JAK-1, 2 and 3 in Children with Down Syndrome and Acute Leukemia.
Authors: Marjolein Blink, Trudy Buitenkamp, Astrid A Danen-van Oorschot, Valerie de Haas, Dirk Reinhardt, Henrik Hasle, Marry M. van den Heuvel, C. Michel Zwaan
Journal: Blood (2009)
One Mutation Fits All
Authors: Paul A. van der Zwaag, van den Maarten Berg, Moniek G. Cox, de Rudolf Boer, Karin Y. van Spaendonck-Zwarts, Robert Hofstra, Ans C. Wiesfeld, Richard N. Hauer, Arthur A. Wilde, Jan Jongbloed, van Peter Tintelen
Journal: Circulation (2010)
Transmembrane TNF-α Facilitates HIV-1 Infection of Podocytes Cultured from Children with HIV-Associated Nephropathy
Authors: Jinliang Li, Jharna R. Das, Pingtao Tang, Zhe Han, Jyoti K. Jaiswal, Patricio E. Ray
Journal: Journal of the American Society of Nephrology (2016)

Studies have shown that podocytes and renal tubular epithelial cells from patients with HIV-associated nephropathy (HIVAN) express HIV-1 transcripts, suggesting that productive infection of renal epithelial cells precipitates development of HIVAN. However, podocytes and renal tubular epithelial cells do not express CD4 receptors, and it is unclear how these cells become productively infected in vivo . We investigated the mechanisms underlying the infection by HIV-1 of podocytes cultured from the urine of children with HIVAN. We observed low–level productive infection on exposure of these cells to primary cell-free HIV-1 supernatants. However, envelope–defective recombinant HIV-1 did not infect the renal epithelial cell lines. Moreover, treatment of podocytes to inhibit endocytic transport or dynamin activity or remove cell surface heparan sulfate proteoglycans reduced infection efficiency. Transfection of CD4− 293T cells with a cDNA expression library developed from a podocyte cell line derived from a child with HIVAN led to the identification of TNF- α as a possible mediator of HIV-1 infection. Overexpression of transmembrane TNF- α in cultured CD4− renal tubular epithelial cells, 293T cells, and HeLa cells enabled the infection of these cells; exposure to soluble TNF- α did not. Immunohistochemistry showed TNF- α expression in podocytes of renal sections from children with HIVAN. Furthermore, we found that TNF- α enhanced NF- κ B activation and integration of HIV-1 into the podocyte DNA. Finally, inhibition of dynamin activity blocked TNF- α– mediated infection. These data establish a role for transmembrane TNF- α in facilitating the viral entry and integration of HIV-1 into the DNA of renal epithelial cells.
ANGI-09COMPARISON OF PROGRESSION PATTERN (PP) AND ADVERSE EVENTS (AES) WITH USE OF BEVACIZUMAB (BEV) ACROSS MULTIPLE LINES IN THE TREATMENT IN GLIOBLASTOMA (GBM)
Authors: Ayesha Baig, Aline Mamo, Maryyam Azam, Petr Kavan
Journal: Neuro-Oncology (2015)

BACKGROUND: RTOG 0825 and AVAGlio studies showed mixed survival results when bev was added to first line GBM treatment. In North America, use of bev is only approved for recurrent disease. Others have explored the reasons for bev failure; two hypotheses included 1) bev promoting distant and diffuse PP as a resistance mechanism 2) AEs related to the use of bev. This study was undertaken to describe and compare PPs and AEs associated with bev in newly diagnosed and recurrent GBM. METHODS: Sixty-four GBM patients treated with bev at McGill University Hospitals between 2008-2014 were identified. 30/64 (46.9%) patients received bev 1st line (B1L) and 34/64 (53.1%) received bev in 2nd line and beyond (B2L+). The median length of treatment was 24.4 weeks (range 0-232.7). Retrospective data collection through chart review for PPs was categorized: local, distant, diffuse and multifocal progression (LoP, DsP, DfP, MfP) or multi-pattern progression (MpP). AEs were documented as per CTCAE version 4.0. RESULTS: B1L vs B2L+ showed following PP: LR 46.7% vs 26.5%, DsP 3.3% vs 2.9%, DfP 20% vs 47%, MfR 10% vs 8.8%, MpP 3.3% vs 11.8%. No difference between B1L vs B2L+ were observed in DsP (p = 0.3) and DfP (p = 0.4) PP. Grade 3/4 AEs in B1L vs B2L + : fatigue 33.3% vs 17.6%, hypertension 26.7% vs 5.9%, thrombocytopenia 26.7% vs 11.8%, neutropenia 26.7% vs 11.8%, anemia 23.3% vs 11.8%, leucopenia 20% vs 8.8%, deep vein thrombosis, 23.3% vs 5.9%, seizures 16.7% vs 8.8%, brain hemorrhage 6.7% vs <1% and delayed wound healing 6.7% vs 2.9%. More total grade 3/4 AEs occurred in B1L (p = 0.000519). CONCLUSION: In our cohort, no PP differences occurred between B1L vs B2L + , suggesting no difference in resistance mechanism. Moreover, similar AEs occurred in B1L and B2L with more grade 3/4 A/Es in B1L group, supporting use in B2L+.
Newly Diagnosed Myeloma Pateints Are at Risk of Venous Thrombotic Events - High Risk Patients Need To Be Identified and Recieve Thromboprophylaxis: The MRC Experience.
Authors: Faith E. Davies, J. Anthony Child, Kim Hawkins, Susan Bell, Julia Brown, Mark T. Drayson, Graham H. Jackson, Gareth J. Morgan
Journal: Blood (2004)
Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.
Authors: Jean-Michel Cayuela, Kheira Beljord, Claude Preudhomme, Helene Cavé, Jean-François Eliahou, Marie-Françoise Auclerc, Judith Landman-Parker, Thierry Leblanc, Yves Perel, Françoise Mechinaud, Geneviève Marguerite, Claudine Schmitt, Gérard Michel, Christiane Vermylen, Virginie Gandemer, Sylvie Chevret, Guy Leverger, Elisabeth Macintyre, André Baruchel
Journal: Blood (2004)
Head and Neck Management of the Cancer Patient.
Journal: Annals of Internal Medicine (1987)

head and neck management of the cancer patient is available in our book collection an online access to it is set as public so you can get it instantly. Our books collection saves in multiple locations, allowing you to get the most less latency time to download any of our books like this one. Kindly say, the head and neck management of the cancer patient is universally compatible with any devices to read.
A STUDY OF HEAD INJURY ADVICE ON RETURN TO SPORT IN ACCIDENT AND EMERGENCY
Authors: R Dhand, D Khamoo, D Eastwood
Journal: British Journal of Sports Medicine (2016)

Return to play (RTP) post head injury is a controversial yet important topic in sport. Repeated head injuries have been linked to long-term neurological conditions such as Chronic Traumatic Encephalopathy (McKee, A. et al, NEN 2008, 68 (7), 709–735). NICE Guidance states that there should be printed advice given to patients for returning to sports (www.nice.org.uk/guidance/cg176/chapter/1- recommendations#discharge-and-follow-up). International consensus guidelines indicated that elite and non-elite athletes should be managed using the same treatment and RTP model. A minimum of 48 hours rest is recommended before attempting a graduated RTP protocol. (McCrory, P.et al CJSM 2013,23(2), 89–117. Some professional bodies recommend 14 days of complete rest (http://www.englandrugby.com/mm/Document/MyRugby/Headcase/01/30/49/33/returntoplayafterconcussion_Neutral.pdf). The project aimed to assess whether RTP advice was given to patients being discharged home from Accident and Emergency (A+E) after a head injury. Firstly, head injury advice cards for all 8 trusts in the Northern Deanery were analysed for advice on RTP. Secondly, there was retrospective analysis of the notes of all A+E patients aged 18–50 who attended University Hospital of North Durham over a 6-month period, and were discharged home. 6 trusts (75%) had no information on when to RTP after a head injury. 326 patients were analysed. 49 patients (15%) attended due to a documented sporting cause. 243 patients (75%) displayed symptoms suggestive of concussion. 2 patients (0.6%) were given advice on when to RTP. Results indicate that we may be neglecting RTP advice for our patients attending A+E with a head injury. A+E departments should be encouraged to include advice on RTP for patients with emphasis on greater education for both healthcare professionals and patients. Further research is needed for the recommended rest period before RTP and the definite long-term effects of repeated head injury.
Decitabine Combined With Chemotherapy For The Treatment Of Refractory Acute Myeloid Leukemia: a Pilot Phase 1 Clinical Study
Authors: Ling Pan, Meng Chen, Yongqian Jia, Xu Cui, Ting Niu, Hong Chang, Hongbing Ma, Jianjun Li, Yuping Gong, Xinchuan Chen, Ting Liu
Journal: Blood (2013)
Disparities of Minor Histocompatibility Antigens in Unrelated Allo-HCT.
Authors: Miroslaw Markiewicz, Urszula Siekiera, Jerzy Wojnar, Iwona Wylezol, Sebastian Giebel, Monika Dzierzak, Agnieszka Karolczyk, Jerzy Holowiecki
Journal: Blood (2007)
A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)
Authors: Angela Dispenzieri, Morie Abraham Gertz, Martha Q Lacy, Kristina Laumann, Betsy R. LaPlant, Shaji Kumar, Francis K Buadi, Suzanne R. Hayman, David Dingli, William J Hogan, Stephen M Ansell, Dennis A. Gastineau, David James Inwards, Ivana N. Micallef, Luis F. Porrata, Patrick B. Johnston, Mark R. Litzow, Thomas E. Witzig
Journal: Blood (2011)
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association
Authors: Biykem Bozkurt, Monica Colvin, Jennifer Cook, Leslie T. Cooper, Anita Deswal, Gregg C. Fonarow, Gary S. Francis, Daniel Lenihan, Eldrin F. Lewis, Dennis M. McNamara, Elfriede Pahl, Ramachandran S. Vasan, Kumudha Ramasubbu, Kismet Rasmusson, Jeffrey A. Towbin, Clyde Yancy
Journal: Circulation (2016)
Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma
Authors: Nathan H. Fowler, Stephen P. Kahanic, Andres Forero, Mihaela C. Munteanu, Glen L. Davis, Peter Brown, Eric Van Den Neste, Fritz C. Offner, Dominique Bron, Myron S. Czuczman
Journal: Blood (2011)
Style modification in breast and Colorectal Cancer Patients: results of a pilot study Long-Survivors
Authors: M.C. Pegoraro, D. Barana, G. Schiavo, I. Fracca, C. Giabardo, C. Forni, M. Padovani, S. Binato, M. Magazù, E. Aitini, F. Adami, R. Ridolfi, G. Porcile, C. Oliani
Journal: Annals of Oncology (2015)
Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL
Authors: Sanghoon Lee, Changhong Yin, Janet Ayello, Erin Morris, Lauren Harrison, Carmella van de Ven, Matthew J. Barth, Rodney R. Miles, Paul J. Galardy, Stanton Goldman, Megan S Lim, Michelle L. Hermiston, Linda McAllister-Lucas, Lisa Giulino-Roth, Sherrie L. Perkins, Mitchell S. Cairo
Journal: Blood (2015)
Outcome after Relapse or Progression Following First Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia. a Retrospective Analysis from the French Society of Bone Marrow Transplantation and Cell Therapies
Authors: Clémence Roux, Karim Tifratene, Nicole Raus, Gerard Socie, Claire Galambrun, Yves Bertrand, Fanny Rialland, Charlotte Jubert, Audrey Contet, Catherine Paillard, Anne Sirvent, Brigitte Nelken, Yves Beguin, Ibrahim Yakoub-Agha, Mohamad Mohty, Jean-Hugues Dalle, Gerard Michel, Christian Pradier, Regis Peffault de Latour, Pierre-Simon Rohrlich
Journal: Blood (2014)
Role of natural lycopene and phytonutrients along with radiotherapy and chemotherapy in high grade gliomas
Authors: T. Puri, P. K. Julka, S. Goyal, O. Nair, D. N. Sharma, G. K. Rath
Journal: Journal of Clinical Oncology (2005)

1561 Objective: The present study was conducted to determine the effect of adding lycopene (antioxidant with potential anticancer activity), to radiotherapy (RT) and chemotherapy in the adjuvant treatment of high grade gliomas, with response at 6 months and time to progression being end points. Methods: The study was conducted from Nov'02-Nov'03. Fifty patients with anaplastic astrocytoma (AA) or GBM were enrolled who had undergone surgical excision but had residual disease. All of them received RT to a dose of 60Gy in 30 fractions over 6 weeks with concomitant Paclitaxel, 60 mg/m2 i/v weekly. They were randomized into two groups: Group A: (n=25) received 8mg of oral lycopene daily, Group B: (n=25) received placebo; along with RT. Informed consent was taken prior to enrollment. Response was evaluated with MRI and brain SPECT at 3 and 6 months post treatment; and 6monthly thereafter. Pre and post RT plasma lycopene levels were monitored using high precision liquid chromatography. Results: Out of 50 patients, 38 were males and 12 females with a mean age of 38 years. 32 patients had GBM while 18 had AA Response at six months post treatment was analyzed using WHO criteria. All patients were alive at 6 months. Pre and post treatment plasma lycopene levels in patients of Group A were 152 and 316 ng/ml and in Group B were 93 and 98 ng/ml. Among Group A (lycopene group): 10 (40%) patients had complete response (CR), 10 (40%) had partial response (PR), 1 (4%) had stable disease (SD), 3 (12%) had progressive disease (PD) while response was not available for 1 patient (4%). Among Group B (placebo group); 5 (20%) patients had CR, 6 (24%) had PR, 1 (4%) had SD, 8 (32%) had PD while response was not available for 5 patients (20%). Overall response in Group A was superior to Group B but was not statistically significant (p = 0.1). Median time to disease progression was 39 wks for Group A and 21 wks for Group B patients (p = 0.14). Conclusions: The addition of lycopene to radiotherapy and chemotherapy in patients with high grade glioma results in positive outcome; both in terms of response rates at 6 months post treatment and time to progression. Further larger studies would be required to arrive at a more definitive Conclusion: No significant financial relationships to disclose.
Six Novel Mutations Identified in the Glycoproteins Ib Alpha, Ib Beta and IX Genes Among Twenty-Two Unrelated Patients with Bernard-Soulier Syndrome in Brazil
Authors: Lucia Helena de Siqueira, Miriam P Beltrame, Fernanda P G Cunha, Marina P Colella, Joyce M Annichino-Bizzacchi, Erich V de Paula, Margareth C. Ozelo
Journal: Blood (2011)
Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis
Authors: Isabella Dotti, Rut Mora-Buch, Elena Ferrer-Picón, Núria Planell, Peter Jung, M Carme Masamunt, Raquel Franco Leal, Javier Martín de Carpi, Josep Llach, Ingrid Ordás, Eduard Batlle, Julián Panés, Azucena Salas
Journal: Gut (2016)

Objective UC is a chronic inflammatory disease of the colonic mucosa. Growing evidence supports a role for epithelial cell defects in driving pathology. Moreover, long-lasting changes in the epithelial barrier have been reported in quiescent UC. Our aim was to investigate whether epithelial cell defects could originate from changes in the epithelial compartment imprinted by the disease. Design Epithelial organoid cultures (EpOCs) were expanded ex vivo from the intestinal crypts of non-IBD controls and patients with UC. EpOCs were induced to differentiate (d-EpOCs), and the total RNA was extracted for microarray and quantitative real-time PCR (qPCR) analyses. Whole intestinal samples were used to determine mRNA expression by qPCR, or protein localisation by immunostaining. Results EpOCs from patients with UC maintained self-renewal potential and the capability to give rise to differentiated epithelial cell lineages comparable with control EpOCs. Nonetheless, a group of genes was differentially regulated in the EpOCs and d-EpOCs of patients with UC, including genes associated with antimicrobial defence (ie, LYZ , PLA2G2A ), with secretory (ie, ZG16 , CLCA1 ) and absorptive (ie, AQP8 , MUC12 ) functions, and with a gastric phenotype (ie, ANXA10 , CLDN18 and LYZ ). A high rate of concordance was found in the expression profiles of the organoid cultures and whole colonic tissues from patients with UC. Conclusions Permanent changes in the colonic epithelium of patients with UC could be promoted by alterations imprinted in the stem cell compartment. These changes may contribute to perpetuation of the disease.
Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy
Authors: Austin G. Kulasekararaj, Azim M Mohamedali, Alexander E Smith, Syed A Mian, Nazia Matto, Terry J Gaymes, Nicholas Lea, Joop Gaken, Ghulam J. Mufti
Journal: Blood (2013)
More Than 4 Cycles of ABVD for the Treatment of Stage I–II Hodgkin’s Lymphoma?.
Authors: Norma Tartas, Marta Zerga, Graciela Alfonso, María P. Amoroso Copello, Isabel Santos, Jorge Korin, Elsa Nucifora, Dorotea Fantl, Patricia Luchetta, Hugo Ferro, Carolina Chacón, Lucía Barazzutti, Alba Scoles, Fernanda Rainieri, Jorge Alberbide, Anahí VijnovichBarón, Gustavo Kusminsky, María Foncuberta, Julio Sánchez Avalos
Journal: Blood (2005)
Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma.
Authors: Shmuel Yaccoby, Wen Ling, Rinku Saha, Fenghuang Zhan, Ron Walker, Guido Tricot, Bart Barlogie, John D. Shaughnessy
Journal: Blood (2005)
Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells
Authors: Florian Weinberger, Kaja Breckwoldt, Simon Pecha, Allen Kelly, Birgit Geertz, Jutta Starbatty, Timur Yorgan, Kai-Hung Cheng, Katrin Lessmann, Tomas Stolen, Marielle Scherrer-Crosbie, Godfrey Smith, Hermann Reichenspurner, Arne Hansen, Thomas Eschenhagen
Journal: Science Translational Medicine (2016)

Human engineered heart tissue derived from induced pluripotent stem cells improves cardiac function in guinea pigs.
Diffuse Vesicular Eruption
Authors: Kirk A. Sidey, Melissa S. J. Willis, Karolyn A. Wanat
Journal: JAMA Dermatology (2016)

An elderly man with chronic lymphocytic leukemia had spreading painful blisters on the hands and feet, and rhinorrhea, cough, and low-grade fever; he had numerous pink to violaceous macules, papules, and patches. What is your diagnosis?
Twenty Units of Blood and Counting
Authors: Emma Brownrigg, Debbie Carr, Michael C. Copeman, Kim Creighton, Catherine Demasi, Julie Domanski, Susan Harrison, Cherry Hodges, Joanne Kanakis, Sharyn Kelleher, Joanna McCosker-Rees, Rachel Prall, Dawn Richardson, Patricia Ryan, Craig Swan, Susan Terry, Julie Tovey, Rosita Van Kuilenberg, Melissa Wills, Cassandra Slader
Journal: Blood (2008)
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy
Authors: Evan Y. Yu, Daniel W. Lin
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma
Authors: Milena Sokolowska, Li-Yuan Chen, Yueqin Liu, Asuncion Martinez-Anton, Carolea Logun, Sara Alsaaty, Rosemarie A. Cuento, Rongman Cai, Junfeng Sun, Oswald Quehenberger, Aaron M. Armando, Edward A. Dennis, Stewart J. Levine, James H. Shelhamer
Journal: Journal of Allergy and Clinical Immunology (2016)
Mutational Analysis of the CBFβ-SMMHC Assembly Competence Domain Identifies a Surface Critical for Multimerization and Inhibition of RUNX1/AML1.
Authors: Linsheng Zhang, Jenice D’Costa, Tanawan Kummalue, Isabel Moreno, Curt I. Civin, Scott W. Hiebert, Alan D. Friedman
Journal: Blood (2005)
Outcome of Relapsed Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) after Allogeneic Hematopoietic Cell Transplantation (HCT).
Authors: Simone Heyn, Rainer Krahl, Thoralf Lange, Ann-Kathrin Eisfeld, Dietger Niederwieser, Haifa K. Al-Ali
Journal: Blood (2007)